Added therapeutic benefit and drug licensing     Hans-Georg Eichler, Harald Enzmann & Guido Rasi pp651 - 652 | doi:10.1038/d41573-019-00068-x One aspect of the ongoing debate about drug pricing is the added therapeutic benefit of new drugs compared with existing — and potentially cheaper — therapies. Here, we discuss the merits and pitfalls of proposals that are being discussed with regard to the role of regulatory agencies in establishing added therapeutic benefit.  Full Text | PDF
NEWS & ANALYSIS
Machine learning brings cell imaging promises into focus     Asher Mullard pp653 - 655 | doi:10.1038/d41573-019-00144-2 Recursion, Janssen, insitro and others are combining high-content phenotypic screening with machine learning to zoom in on emerging opportunities in target discovery, hit identification, toxicity testing and more.  Full Text | PDF
NEWS IN BRIEF
Alzheimer prevention failure rattles field, anew     Asher Mullard p656 | doi:10.1038/d41573-019-00139-z Full Text | PDF
First in vivo CRISPR candidate enters the clinic     Asher Mullard p656 | doi:10.1038/d41573-019-00140-6 Full Text | PDF
Longer-lasting HIV drugs     Asher Mullard p656 | doi:10.1038/d41573-019-00141-5 Full Text | PDF
BIOBUSINESS BRIEFS
TRIC-B: an under-explored druggable ion channel     Zicheng Hu & Olga Gulyaeva p657 | doi:10.1038/d41573-019-00131-7 Full Text | PDF
Transition probabilities for clinical trials: investigating individual diseases     Kathleen L. Miller, Dina Rabinovitz & Kirk W. Kerr p658 | doi:10.1038/d41573-019-00124-6 Full Text | PDF
AN AUDIENCE WITH
Jessica Mega     Asher Mullard pp660 - 661 | doi:10.1038/d41573-019-00132-6 Jessica Mega, chief medical and scientific officer at Verily, discusses why the Google X spin out is building a new clinical trial operating system.  Full Text | PDF
FROM THE ANALYST'S COUCH
Non-Hodgkin lymphoma therapy landscape     Kritika Chaudhari, Salman Rizvi & Basharut A. Syed pp663 - 664 | doi:10.1038/d41573-019-00051-6 This article examines the market for non-Hodgkin lymphoma, for which there are a growing number of treatment options in addition to chemotherapy and anti-CD20 antibodies, and provides future market predictions.  Full Text | PDF